please find below an announcement for a webinar organized by Kakushin group about the changes introduced by the new drug law in Germany and its potential implications. I will give an overview from a pricing perspective.
Cheers
Ulf
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgAHNAH4UcSQa6sgooP8RVX2jdiWm7IksPgju10qaFsNvJEWqB83lPpxCV47hUM_Vr2BUZ6kafLG3zYD8hyE2J9WLIjdFqm_5L2LASORKSv9Qg8JjKoJPDADKoZPPagCEojJsFFmIraL0Y/s400/AMNOG.jpg.png)
Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
No comments:
Post a Comment